Early therapeutics development with phase II emphasis

Ended Definitive Contract Awarded Last action

Contract number
HHSN261200622001C
Awardee
Awarding agency
Obligated
$5,944,623

Award facts

Opportunity
Contract value 21% obligated
  • $20,301,709.00 Current, with exercised options
  • $28,515,413.00 Potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
Not on record
Set-aside
No set-aside
Competition
Full and Open Competition · 11 offers Negotiated Proposal / Quote
Pricing
Cost No Fee
Place of performance
Chicago, IL 60637, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 24 · Final_close_process -deobligate FY 10 funds under prism line #16. -$15,294
Other Administrative Action 22 -$15,294
Other Administrative Action 23 · Final_close_process -deobligate FY 11 funds under prism line #14. $15,294
Funding Only Action 21 · Add arra funds to correct an invoice payment $15,294
Change Order 20 · Deobligate FY 11 funds under prism line #14. -$95,369
Funding Only Action 19 · Final_close_process - -$102,114
Other Administrative Action 18 $0
Other Administrative Action 17 · Other functions the purpose of this modification is to extend the arra portion of this contract through november 30, 2012. $0
Other Administrative Action 16 · The purpose of this modification is to extend the arra portion of this contract through november 30, 2012. $0
Funding Only Action 15 $141,161
Funding Only Action 14 $127,336
Funding Only Action 13 $185,440
Funding Only Action 12 $278,906
Other Administrative Action 11 $123,792
Exercise an Option 10 $207,512
Funding Only Action 9 · Biomedical (basic) $381,750
Funding Only Action 8 · Recovery act - actnow clinical trial 8418 under "early therapeutics development with phase II emphasis" arra::yes::arra $650,000
Other Administrative Action 7 $0
Exercise an Option 6 $272,360
Funding Only Action 5 $662,981
Funding Only Action 4 $852,824
Funding Only Action 3 $543,637
Funding Only Action 2 $516,566
Other Administrative Action 1 $480,296
Original award $717,545
Show all 25

About this award

Written by GovTribe AI ·

This federal contract award, valued at $28,515,413.00, was issued by the National Cancer Institute (NCI) to the University of Chicago for the "EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS" effort. The contract is a definitive contract with a cost-no-fee pricing type and does not have a set-aside designation. The University of Chicago, a renowned private research university, will conduct cutting-edge research and provide specialized services in areas critical to national priorities, such as medicine and cancer research. This contract supports the NCI's mission to advance cancer research and therapeutics development. The University of Chicago is a major recipient of federal awards and has a strong track record of collaborating with other academic institutions, national laboratories, and industry partners on contract efforts.

Quick answers

Who was awarded contract HHSN261200622001C?

HHSN261200622001C was awarded to The University Of Chicago by National Cancer Institute (National Institutes of Health) on January 1, 2006.

How much is contract HHSN261200622001C worth?

The government has obligated $5,944,623 on HHSN261200622001C. Its current value, with exercised options, is $20,301,709. Its potential value, with all options, is $28,515,413.

Was contract HHSN261200622001C competed?

The extent of competition for HHSN261200622001C was full and open competition. The government received 11 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login